BACKGROUND AND PURPOSE: Although the efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing future vascular events for patients with coronary heart disease is established, less is known about the precise benefit of these agents among patients with stroke. We evaluated whether use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers reduces future vascular events in persons with prior stroke. METHODS: We searched PubMed, Cochrane Central Register of Controlled Trials, and bibliographies of relevant trials and recent review articles to identify randomized controlled trials. Relative risk with 95% CI was used as a measure of the association between use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and risks of major vascular event (nonfatal stroke, nonfatal myocardial infarction, or death from cardiovascular causes) or stroke (ischemic or hemorrhagic) after pooling data across trials. RESULTS: Eight randomized controlled trials with 29 667 participants were identified. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in persons with prior stroke was associated with lower risks of future major vascular events (relative risk, 0.91; 95% CI, 0.87-0.97; P=0.001; number needed to treat=71) and recurrent stroke (relative risk, 0.93; 95% CI, 0.86-0.99; P=0.03; number needed to treat=143). Heterogeneity was found among studies for end points of major vascular events (P=0.02, I(2)=61%) but not recurrent stroke (P=0.38, I(2)=6%). In subgroup analyses, there was generally no obvious heterogeneity among different study characteristics. CONCLUSIONS: Treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker has a clear but rather modest effect on reducing vascular risk in persons with prior stroke.
BACKGROUND AND PURPOSE: Although the efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing future vascular events for patients with coronary heart disease is established, less is known about the precise benefit of these agents among patients with stroke. We evaluated whether use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers reduces future vascular events in persons with prior stroke. METHODS: We searched PubMed, Cochrane Central Register of Controlled Trials, and bibliographies of relevant trials and recent review articles to identify randomized controlled trials. Relative risk with 95% CI was used as a measure of the association between use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and risks of major vascular event (nonfatal stroke, nonfatal myocardial infarction, or death from cardiovascular causes) or stroke (ischemic or hemorrhagic) after pooling data across trials. RESULTS: Eight randomized controlled trials with 29 667 participants were identified. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in persons with prior stroke was associated with lower risks of future major vascular events (relative risk, 0.91; 95% CI, 0.87-0.97; P=0.001; number needed to treat=71) and recurrent stroke (relative risk, 0.93; 95% CI, 0.86-0.99; P=0.03; number needed to treat=143). Heterogeneity was found among studies for end points of major vascular events (P=0.02, I(2)=61%) but not recurrent stroke (P=0.38, I(2)=6%). In subgroup analyses, there was generally no obvious heterogeneity among different study characteristics. CONCLUSIONS: Treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker has a clear but rather modest effect on reducing vascular risk in persons with prior stroke.
Authors: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel Journal: Lancet Date: 2002-03-23 Impact factor: 79.321
Authors: Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon Journal: N Engl J Med Date: 2008-08-27 Impact factor: 91.245
Authors: Fred Stephen Sarfo; Linda Meta Mobula; Osei Sarfo-Kantanka; Sheila Adamu; Jacob Plange-Rhule; Daniel Ansong; Rexford Adu Gyamfi; James Duah; Bertha Abraham; David Ofori-Adjei Journal: J Neurol Sci Date: 2018-11-15 Impact factor: 3.181
Authors: Myrna M E van Dongen; Karoliina Aarnio; Nicolas Martinez-Majander; Jani Pirinen; Juha Sinisalo; Mika Lehto; Markku Kaste; Turgut Tatlisumak; Frank-Erik de Leeuw; Jukka Putaala Journal: Ann Med Date: 2019-02-14 Impact factor: 4.709